Industry-leading hemp and cannabinoid solutions provider GVB Biopharma unveils high-purity Cannabicitran (CBT) Isolate, broadening its suite of rare cannabinoid offerings.

PRINEVILLE, Ore., March 13, 2025 /PRNewswire/ -- GVB Biopharma, a premier developer, manufacturer, and global distributor of hemp-derived cannabinoid products, is proud to announce the launch of its new CBT Isolate. This latest product addition reinforces GVB Biopharma's commitment to innovation and quality by offering advanced, pure, and consistent cannabinoid ingredients to clients around the world.

CBT, also known as Cannabicitran, is a rare cannabinoid that is quickly emerging in the hemp and wellness industries. Like other rare cannabinoids, CBT demonstrates distinct properties and potential benefits for users seeking new functional product formulations. With rigorous in-house testing and a commitment to quality assurance, GVB Biopharma's CBT Isolate is produced to exacting standards, making it ideal for use in tinctures, topicals, edibles, and more.

"Our introduction of CBT Isolate underscores our dedication to leading the industry in both quality and innovation," said Drew Spiegel, CEO of GVB Biopharma. "Rare cannabinoids are at the forefront of new product development, and GVB Biopharma strives to give our customers the best-in-class, high-purity ingredients they need to create differentiated and effective formulations."

Key Benefits and Features of GVB Biopharma's CBT Isolate

• High Purity: Produced under stringent quality controls using state-of-the-art extraction and refinement processes.
• Reliable Consistency: GVB Biopharma's certified manufacturing ensures uniform quality and potency with every batch.
• Versatile Applications: Suitable for a wide range of product formats, including oils, beverages, supplements, and topicals.
• Exceptional Quality Assurance: Backed by rigorous testing, transparent COAs, and expert support.

"In a rapidly evolving cannabinoid landscape, the introduction of CBT Isolate gives our clients the opportunity to remain on the cutting edge," said Jack Feldman, President of GVB Biopharma. "We're excited to see how brands will utilize CBT in their product development and how it will expand the possibilities of what cannabinoid formulations can offer."

With the addition of CBT Isolate to its diverse portfolio, GVB Biopharma continues to reinforce its position as a trusted partner for businesses seeking high-quality, innovative hemp-derived solutions. The launch reflects GVB Biopharma's dedication to empowering brands with the tools and expertise necessary to create differentiated consumer experiences within the dynamic cannabis and wellness sectors.

For more information on GVB Biopharma's CBT Isolate or to place an order, visit the CBT Isolate Product Page.

About GVB Biopharma

GVB Biopharma is an industry-leading developer, manufacturer, and global distributor of hemp and cannabinoid-based products. With cutting-edge extraction technologies, rigorous testing, and robust quality assurance protocols, GVB Biopharma provides a full suite of solutions. The company's ongoing commitment to innovation, compliance, and customer satisfaction continues to set it apart as a trusted partner in the global cannabinoid market.

For media inquiries, please contact:

Gabi de la Guardia

(801) 203-0887

391749@email4pr.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/gvb-biopharma-expands-product-portfolio-with-launch-of-premium-cbt-isolate-302400593.html

SOURCE GVB Biopharma